66th ASH Annual Meeting: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis

Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, Clinical trials, Apoptosis, Combination therapy, Adult, MPN, Clinical Practice (Health Services and Quality), Drug development, Clinical Research, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Treatment Considerations, Adverse Events, Myeloid Malignancies, Study Population, Human

Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)

Moderators:

Lindsay A.M. Rein, MD, Duke Cancer Institute and Jean-Jacques Kiladjian, MD, PhD, Paris Cité University

Disclosures:

Rein: Abbvie: Consultancy; Sobi: Consultancy; DAVA Oncology: Other: Speaker, conference participant; Incyte: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Morphpsys: Consultancy; Novartis: Consultancy, Honoraria, Other: Site Principal Investigator for clinical trial, Research Funding; Sumitomo Dainippon Pharma Oncology: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Cogent Biosciences: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Protagonist: Other: Site Principal Investigator for clinical trial, Research Funding; Geron: Other: Site Principal Investigator for clinical trial, Research Funding; Blueprints Medicine: Other: Site Principal Investigator for clinical trial, Research Funding; Merck: Other: Site Principal Investigator for clinical trial, Research Funding; PharmaEssentia: Other: Site Principal Investigator for clinical trial, Research Funding; Karyopharm: Other: Site Principal Investigator for clinical trial, Research Funding; Telios Pharma: Research Funding; Silence Therapeutics: Research Funding. Kiladjian: Novartis: Consultancy; GSK: Consultancy; AOP Health: Consultancy; Incyte: Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria; PharmaEssentia: Honoraria.

This session focuses on the latest advancements in treating myeloproliferative neoplasms (MPNs), with a spotlight on innovative therapies and key clinical trials. Presentations will cover a range of emerging treatments in combination with ruxolitinib for myelofibrosis to the use of novel therapies in various MPN and MDS/MPN subtypes. Attendees will gain insights into the efficacy, safety, and clinical benefits of these novel therapies, particularly for patients with suboptimal responses to existing treatments or those who are treatment-naive. By focusing on cutting-edge clinical studies and combination therapies, this session aims to provide healthcare professionals with the knowledge to optimize treatment strategies, improve patient outcomes, and advance care across the spectrum of myeloproliferative neoplasms.

4:30 PM

997

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Claire Harrison¹, Lynette C.Y. Chee, MBBS, PhD, FRACP, FRCPA², Timothy Devos, MD, PhD³^*, Maria Laura Fox, MD⁴^*, Alessandra Iurlo, MD, PhD⁵^*, Francesca Palandri, MD, PhD⁶^*, David M Ross, MD, PhD, FRACP, FRCPA⁷^*, Shuhying Tan, FRACP, FRCPA, MBBS⁸^*, Alessandro Maria Vannucchi⁹, Marielle Wondergem, MD, PhD¹⁰, Michael Pace¹¹^*, Hongying Wang, MS¹¹^*, Ming Yang, PhD¹¹^*, Ying Jiang, PhD, MBA¹¹^*, Suresh Bobba¹¹^*, Montagu Hankin, MSc¹¹^*, Chris Materna, MSc¹¹^*, Christine Graham, PhD¹¹^*, Sanjay Thamake, PhD, MBA¹¹^*, Christopher Rovaldi, MSc¹¹^*, Dena Grayson, MD, PhD¹¹^* and Jen L. Salstrom, MD, PhD¹¹

¹Guy's and St Thomas' NHS Foundation Trust, London, ENG, United Kingdom
²Department of Clinical Haematology and Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Australia
³Department of Hematology, University Hospitals Leuven, Leuven, Belgium
⁴Vall d'Hebron University Hospital, Barcelona, Spain
⁵Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
⁶IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Istituto di Ematologia "Seràgnoli", Bologna, Italy
⁷Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia
⁸Department of Haematology, St Vincent’s Hospital, Melbourne, Australia
⁹Department of Experimental and Clinical Medicine, Centro di Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, University of Florence, Firenze, Tuscany, Italy
¹⁰Department of Hematology, Amsterdam University Medical Centers, Amsterdam, Netherlands
¹¹Kero's Therapeutics, Lexington

4:45 PM

998

Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)

John O. Mascarenhas, MD¹, Salman Otoukesh, MD², Terrence Bradley, MD³, Bart L. Scott, MD⁴, Habte A. Yimer, MD⁵, Souria Dougherty, MBA⁶^*, Lixian Peng, PhD⁶^*, Fei Huang, PhD⁶, Ying Wan, MD, PhD⁶^*, Faye M. Feller, MD⁶, Vivian Rodolf, MD⁶, Judy Ho, BS⁶^*, Tymara Berry, MD⁶^* and Andrew T. Kuykendall, MD⁷

¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
²Hematology and HCT, City of Hope National Medical Center, Duarte, CA
³University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
⁴Fred Hutchinson Cancer Center, Seattle, WA
⁵Texas Oncology/ US Oncology Research, Tyler, TX
⁶Geron Corporation, Foster City, CA
⁷Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

5:00 PM

999

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, MD¹, Meixian Huang²^*, Swati Goel, MD³, Sharon Bledsoe¹^*, Naveen Pemmaraju, MD⁴, Tapan M. Kadia, MD¹, Prithviraj Bose, MD¹, Jo Ishizawa, MD, PhD⁵, Guillermo Montalban-Bravo, MD¹, Mi-Ae Lyu²^*, Tara Sadeghi⁶^*, Simrit Parmar, MBBS², Christopher R. Flowers, MD, MS² and Hagop M. Kantarjian, MD¹

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
³Montefiore Einstein Comprehensive Cancer Center, Blood Cancer Institute, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX
⁵Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Cellenkos Inc., Houston, TX

5:15 PM

1000

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas, MD¹, Viola Maria Popov, MD, PhD, MSc², Sanjay Mohan, MD³, Zübeyde Nur Özkurt, Prof.⁴^*, Jean-Jacques Kiladjian, MD, PhD⁵, Haifa Kathrin Al-Ali, MD; PhD⁶^*, Andrew Charles Perkins, MBBS, PhD⁷, Zhuying Huang, PhD⁸^*, Hope Qamoos, NP⁸^*, Jesse McGreivy, MD⁸^*, Wayne Rothbaum, MS⁸^*, Srdan Verstovsek, MD, PhD⁸ and Maciej Kaźmierczak, MD, PhD⁹^*

¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
²Colentina Clinical Hospital Bucharest, Hematology Department, Pitesti, Arges, Romania
³The Vanderbilt Clinic, Nashville, TN
⁴Gazi University, Faculty of Medicine, Department of Hematology, Ankara, Turkey
⁵Hopital Saint-Louis, Paris, France
⁶University Hospital Halle, Halle (Saale), Germany
⁷The Alfred Hospital and Monash University, Melbourne, Australia
⁸Kartos Therapeutics, Inc., Redwood City, CA
⁹University of Medical Sciences, Poznan, Poland

5:30 PM

1001

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Peter T. Tan, MBBS¹, Ross Baker, MBBS²^*, Sung-Eun Lee, MD, PhD³^*, Anne Marie Watson, FRACP, FRCPA, MBBS⁴, Stanley Cheung, MD, PhD⁵^*, Shang-Ju Wu⁶^*, Chih-Cheng Chen, MD, PhD⁷, Shuhying Tan, FRACP, FRCPA, MBBS⁸^*, Pankit Vachhani, MD⁹^*, Tsai-Yun Chen¹⁰^*, Jae Hoon Lee¹¹^*, Hui-Hua Hsiao, MD, PhD¹²^*, Ji Yun Lee, MD¹³, Won Sik Lee¹⁴^*, Lucia Masarova, MD¹⁵, Jana Baskar, MBBS, BMedSc¹⁶^*, Wolfgang Jarolimek, PhD¹⁶^* and Joanna Leadbetter¹⁶^*

¹One Clinical Research Pty Ltd, Nedlands, Australia
²Perth Blood Institute, Murdoch University, Perth, Australia
³Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of (South)
⁴Liverpool Hospital SW Area Pathology Service, Liverpool, Nsw, AUS
⁵ICON Cancer Care, Kurralta Park, Australia
⁶Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
⁷Chang Gung Memorial Hospital-Chiayi, Taichung, Taiwan, Taiwan
⁸Department of Haematology, St Vincent’s Hospital, Melbourne, Australia
⁹Division of Hematology/Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
¹⁰National Cheng Kung University Hospital Clinical Trial Center, Tainan, Taiwan
¹¹Gachon University Gil Medical Center, Incheon, Korea, Republic of (South)
¹²Kaohsiung Medical University, Kaohsiung, Taiwan
¹³Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South)
¹⁴Internal Medicine, Hemato-Oncology, Inje University Busan Paik Hospital, Busan, Korea, Republic of (South)
¹⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁶Syntara Limited, Frenchs Forest, NSW, Australia

5:45 PM

1002

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan¹^*, Lan Ma²^*, Qiuling Wu, PhD³^*, Hong Liang⁴^*, Wei Wang⁵^*, Lijun Mu⁶^*, Hai Lin⁷^*, Hebing Zhou⁸^*, Hong-xia Shi, MD⁹^*, Jinghua Wang¹⁰^* and Hongmei Jing, MD^11,12

¹Department of Hematology, Peking Union Medical College Hospital, Beijing, China
²Peking University Third Hospital, Beijing, China
³Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, AL, China
⁴Department of Hematology & Oncology,Harbin Institute of Hematology & Oncology, haerbin, China
⁵Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China
⁶The Second Hospital of Dalian Medical University, Dalian, China
⁷Department of hematology, First Hospital of Jilin University, Jilin, China
⁸Department of Hematology, Beijing Luhe Hospital, Capital Medical University, Beijing, China
⁹0Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Beijing, CHN
¹⁰The 2nd Affiliated Hospital of Harbin Medical University, Haerbin, Heilongjian, CHN
¹¹Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China
¹²Department of Hematology, Peking University Third Hospital, Beijing, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

634.O2.6 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis